231
Participants
Start Date
February 28, 2014
Primary Completion Date
January 26, 2017
Study Completion Date
February 27, 2017
avatrombopag (lower baseline platelet count)
60 mg avatrombopag (3 x 20 mg tablets)
placebo (lower baseline platelet count)
60 mg placebo (3 x 20 mg matching placebo tablets)
avatrombopag (higher baseline platelet count)
40 mg avatrombopag (2 x 20 mg tablets)
placebo (higher baseline platelet count)
40 mg placebo (2 x 20 mg matching placebo tablets)
Lancaster
Long Beach
Los Angeles
Sacramento
San Bernardino
San Francisco
Jacksonville
Palmetto Bay
Tampa
New Orleans
Rochester
Minneapolis
Jackson
New York
The Bronx
Philadelphia
Pittsburgh
Dallas
Harlingen
Houston
San Antonio
Pilar
Ciudad Autonoma Buenos Aires
Mendoza
Camperdown
Adelaide
Bedford Park
Linz
Vienna
Brussels
Leuven
Porto Alegre
São José do Rio Preto
São Paulo
London
Toronto
La Serena
Santiago
Changsha
Nanjing
Shanghai
Beijing
Strasbourg
Grenoble
Reims
Clermont-Ferrand
Amiens
Vandœuvre-lès-Nancy
Freiburg im Breisgau
Cologne
Herne
Kiel
Hamburg
Békéscsaba
Budapest
Dunaújváros
Gyula
Kaposvár
Kecskemét
Szombathely
Zalaegerszeg
San Giovanni Rotondo
Bari
Bologna
Genova
Milan
Modena
Palermo
Udine
Katowice
Lodz
Mysłowice
Szczecin
Wroclaw
Coimbra
Lisbon
Porto
Viana do Castelo
Vila Real
Viseu
Chuncheon
Guri-si
Seongnam-si
Suwon
Yangsan
Hwasun
Busan
Daegu
Incheon
Seoul
Barcelona
Pontevedra
Seville
Valencia
Valladolid
Kaohsiung City
Taichung
Tainan City
Taipei
Taoyuan
Bangkoknoi
Ratchathewi
Khlong Luang
Mueang Nonthaburi
Truro
London
Manchester
Wolverhampton
Leeds
Eisai Inc.
INDUSTRY